264 filings
Page 5 of 14
8-K
2d2s9z1o d2bna6m73qw
16 Mar 21
Departure of Directors or Certain Officers
4:11pm
8-K
rydb26 bixtov
15 Mar 21
Other Events
6:15am
8-K
equ5q4i7yosb2z60ic
10 Mar 21
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD
7:03am
8-K
tdchna6fqout32uf xx9
23 Feb 21
Results of Operations and Financial Condition
4:08pm
8-K
rbl8172m
16 Feb 21
Other Events
7:05am
8-K
ub00nxk4xg6po
9 Feb 21
Departure of Directors or Certain Officers
4:12pm
8-K
l8565
11 Jan 21
Results of Operations and Financial Condition
8:05am
8-K
yxri5f7zoc
18 Dec 20
Amendments to Articles of Incorporation or Bylaws
8:47am
8-K
y2mhod
7 Dec 20
No severe vaso-occlusive events (VOEs) reported through 24 months of follow-up in Group C patients
4:35pm
8-K
hlfx5n uh61j1mv
7 Dec 20
Bristol Myers Squibb and bluebird bio Present Data Highlighting
8:01am
8-K
d0x6k7krf8
4 Dec 20
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to
8:15am
8-K
sk4xav3j0dy4l
4 Nov 20
Results of Operations and Financial Condition
4:08pm
8-K
9pp0vsztflqa2z 79oqu
2 Oct 20
Other Events
6:06am
8-K
zto woznvdukvanti
1 Oct 20
Departure of Directors or Certain Officers
7:00am
8-K
etwqzywvrz l2cwq
23 Sep 20
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need
7:01am
8-K
7kr y15cv3i4meoxxk
22 Sep 20
Other Events
7:53am
8-K
m9mqbreg2yo1
31 Aug 20
Other Events
6:29am
8-K
gmqiow
18 Aug 20
Departure of Directors or Certain Officers
4:23pm
8-K
s885pa0gpz
11 Aug 20
Departure of Directors or Certain Officers
7:21am
8-K
jar4q
5 Aug 20
Other Events
4:14pm